Compare Natera Inc. Common Stock (NTRA) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Relay Therapeutics Inc. Common Stock trades at $16.91 (market cap $3.74B). The key difference: Natera Inc. Common Stock is far larger — about 15.2× Relay Therapeutics Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Relay Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| NTRA | RLAY | |
|---|---|---|
Market Cap | $57.03B | $3.74B |
Volume | 1,131,157 | 2,936,788 |
Sector | Health | Health |
52-Week High | $425.64 | $20.75 |
52-Week Low | $179.42 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $56.18B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
